Alexion Pharma (ALXN) Tops Q3 EPS by 15c; Guides Above Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Reports Third Quarter 2015 Results
October 29, 2015 6:30 AM EDTSoliris® (eculizumab) Net Product Sales of $665.4 Million; Increased 20% Year-on-Year Despite 9% Currency Headwinds; 29% Volume Increase Year-on-Year -
- 2015 Non-GAAP EPS Guidance Increased to $4.92 to $4.97 -
Strensiq (asfotase alfa) Approved in the United States, European Union, Japan and Canada for Hypophosphatasia (HPP)
Kanuma (sebelipase alfa) Approved in the European Union for Lysosomal Acid Lipase Deficiency (LAL-D)
Completed Enrollment in Registration Trial of Eculizumab in Refractory MG and Progressed Registration Trials in Relapsing NMO and DGF
Advanced Complement and Metabolic Pipelines, Including ALXN 1210 and SBC-103
CHESHIRE, Conn.--(BUSINESS... More
